More than 6 Months of Teriparatide Treatment Was More Effective for Bone Union than Shorter Treatment Following Lumbar Posterolateral Fusion Surgery.

Ohtori S, Orita S, Yamauchi K, Eguchi Y, Ochiai N, Kuniyoshi K, Aoki Y, Nakamura J, Miyagi M, Suzuki M, Kubota G, Inage K and 8 more

Show all authors

Sainoh T, Sato J, Shiga Y, Abe K, Fujimoto K, Kanamoto H, Inoue G, Takahashi K

Asian spine journal28 Jul 2015Cited by 50 (Europe PMC)

PMID26240717PMCIDPMC4522448DOI10.4184/asj.2015.9.4.573PepBankPUB-26240717

Read at source PubMedAsk about this study

Jump to 6 results

Summary

The text of this summary is not shown here, because the article license does not allow reuse. Read it at the source (opens in a new tab)

Text rights: CC BY-NC. Results still quote short attributed sentences.

Results from this study6

6 results from studies that gave the peptide. 6 results from people.

01HumanObservational studyEfficacy outcome
In women with osteoporosis after lumbar fusion, long-duration teriparatide had a higher bone union rate than risedronate.
In plain wordsIn women after lumbar fusion, long-duration teriparatide was linked to a higher bone union rate than risedronate.
Peptide
Teriparatide (PTH 1-34)
Outcome
IncreaseBone union rate with long treatment versus risedronate
Study
n = 30
Comparator
risedronate
Outcome group
Bone and joint · Musculoskeletal
Studied dose
20 µg daily · subcutaneous · average 13.0 monthsAs given in this study (human).
Measurements
Bone union rate
92%
long-duration teriparatide
Bone union rate
70%
bisphosphonate (risedronate)
Source sentences
Summary
Bone union rate and average duration for bone union were 92% and 7.5 months in the long-duration treatment group, 80% and 8.5 months in the short-duration treatment group, and 70% and 10.0 months in the bisphosphonate treatment group, respectively.
4 context sentences(design, population, supporting numbers)
Summary · context
Results of bone union rate and average duration for bone union in the teriparatide treatment groups were significantly superior to those in the bisphosphonate treatment group (p<0.05); whereas, significantly superior results were observed in long-duration treatment group when compared with short-dur…
Summary · context
short-duration treatment (average, 5.5 months; n=15; daily subcutaneous injection of 20 µg teriparatide)
Summary · context
long-duration treatment (average, 13.0 months; n=15; daily subcutaneous injection of 20 µg teriparatide), and bisphosphonate treatment (average, 13.0 months; n=15; weekly oral administration of 17.5 mg risedronate).
Summary · context
All patients underwent PLF with a local bone graft. Fusion rate and duration of bone union were evaluated 1.5 years after surgery.
Report a problemFND-2624071701
02HumanObservational studyEfficacy outcome
In women after lumbar fusion, long-duration teriparatide had a shorter time to bone union than risedronate.
In plain wordsIn women after lumbar fusion, long-duration teriparatide was linked to faster bone union than risedronate.
Peptide
Teriparatide (PTH 1-34)
Outcome
DecreaseTime to bone union with long treatment versus risedronate
Study
n = 30
Comparator
risedronate
Outcome group
Bone and joint · Musculoskeletal
Studied dose
20 µg daily · subcutaneous · average 13.0 monthsAs given in this study (human).
Measurements
Time to bone union
7.5 months
long-duration teriparatide
Time to bone union
10 months
bisphosphonate (risedronate)
Source sentences
Summary
Bone union rate and average duration for bone union were 92% and 7.5 months in the long-duration treatment group, 80% and 8.5 months in the short-duration treatment group, and 70% and 10.0 months in the bisphosphonate treatment group, respectively.
4 context sentences(design, population, supporting numbers)
Summary · context
Results of bone union rate and average duration for bone union in the teriparatide treatment groups were significantly superior to those in the bisphosphonate treatment group (p<0.05); whereas, significantly superior results were observed in long-duration treatment group when compared with short-dur…
Summary · context
short-duration treatment (average, 5.5 months; n=15; daily subcutaneous injection of 20 µg teriparatide)
Summary · context
long-duration treatment (average, 13.0 months; n=15; daily subcutaneous injection of 20 µg teriparatide), and bisphosphonate treatment (average, 13.0 months; n=15; weekly oral administration of 17.5 mg risedronate).
Summary · context
All patients underwent PLF with a local bone graft. Fusion rate and duration of bone union were evaluated 1.5 years after surgery.
Report a problemFND-2624071702
03HumanObservational studyEfficacy outcome
In women after lumbar fusion, short-duration teriparatide had a higher bone union rate than risedronate.
In plain wordsIn women after lumbar fusion, short-duration teriparatide was linked to a higher bone union rate than risedronate.
Peptide
Teriparatide (PTH 1-34)
Outcome
IncreaseBone union rate with short treatment versus risedronate
Study
n = 30
Comparator
risedronate
Outcome group
Bone and joint · Musculoskeletal
Studied dose
20 µg daily · subcutaneous · 5.5 monthsAs given in this study (human).
Measurements
Bone union rate
80%
short-duration teriparatide
Bone union rate
70%
risedronate
Source sentences
Summary
Bone union rate and average duration for bone union were 92% and 7.5 months in the long-duration treatment group, 80% and 8.5 months in the short-duration treatment group, and 70% and 10.0 months in the bisphosphonate treatment group, respectively.
4 context sentences(design, population, supporting numbers)
Summary · context
Results of bone union rate and average duration for bone union in the teriparatide treatment groups were significantly superior to those in the bisphosphonate treatment group (p<0.05); whereas, significantly superior results were observed in long-duration treatment group when compared with short-dur…
Summary · context
short-duration treatment (average, 5.5 months; n=15; daily subcutaneous injection of 20 µg teriparatide)
Summary · context
long-duration treatment (average, 13.0 months; n=15; daily subcutaneous injection of 20 µg teriparatide), and bisphosphonate treatment (average, 13.0 months; n=15; weekly oral administration of 17.5 mg risedronate).
Summary · context
All patients underwent PLF with a local bone graft. Fusion rate and duration of bone union were evaluated 1.5 years after surgery.
Report a problemFND-2624071703
04HumanObservational studyEfficacy outcome
In women after lumbar fusion, short-duration teriparatide had a shorter time to bone union than risedronate.
In plain wordsIn women after lumbar fusion, short-duration teriparatide was linked to faster bone union than risedronate.
Peptide
Teriparatide (PTH 1-34)
Outcome
DecreaseTime to bone union with short treatment versus risedronate
Study
n = 30
Comparator
risedronate
Outcome group
Bone and joint · Musculoskeletal
Studied dose
20 µg daily · subcutaneous · 5.5 monthsAs given in this study (human).
Measurements
Time to bone union
8.5 months
short-duration teriparatide
Time to bone union
10 months
risedronate
Source sentences
Summary
Bone union rate and average duration for bone union were 92% and 7.5 months in the long-duration treatment group, 80% and 8.5 months in the short-duration treatment group, and 70% and 10.0 months in the bisphosphonate treatment group, respectively.
4 context sentences(design, population, supporting numbers)
Summary · context
Results of bone union rate and average duration for bone union in the teriparatide treatment groups were significantly superior to those in the bisphosphonate treatment group (p<0.05); whereas, significantly superior results were observed in long-duration treatment group when compared with short-dur…
Summary · context
short-duration treatment (average, 5.5 months; n=15; daily subcutaneous injection of 20 µg teriparatide)
Summary · context
long-duration treatment (average, 13.0 months; n=15; daily subcutaneous injection of 20 µg teriparatide), and bisphosphonate treatment (average, 13.0 months; n=15; weekly oral administration of 17.5 mg risedronate).
Summary · context
All patients underwent PLF with a local bone graft. Fusion rate and duration of bone union were evaluated 1.5 years after surgery.
Report a problemFND-2624071704
05HumanObservational studyEfficacy outcome
In women after lumbar fusion, long-duration teriparatide had a higher bone union rate than short-duration treatment.
In plain wordsIn women after lumbar fusion, longer teriparatide treatment was linked to a higher bone union rate than shorter treatment.
Peptide
Teriparatide (PTH 1-34)
Outcome
IncreaseBone union rate with long versus short treatment
Study
n = 30
Comparator
short-duration teriparatide
Outcome group
Bone and joint · Musculoskeletal
Studied dose
20 µg daily · subcutaneous · 13.0 monthsAs given in this study (human).
Measurements
Bone union rate
92%
long-duration teriparatide
Bone union rate
80%
short-duration teriparatide
Source sentences
Summary
Bone union rate and average duration for bone union were 92% and 7.5 months in the long-duration treatment group, 80% and 8.5 months in the short-duration treatment group, and 70% and 10.0 months in the bisphosphonate treatment group, respectively.
4 context sentences(design, population, supporting numbers)
Summary · context
Results of bone union rate and average duration for bone union in the teriparatide treatment groups were significantly superior to those in the bisphosphonate treatment group (p<0.05); whereas, significantly superior results were observed in long-duration treatment group when compared with short-dur…
Summary · context
short-duration treatment (average, 5.5 months; n=15; daily subcutaneous injection of 20 µg teriparatide)
Summary · context
long-duration treatment (average, 13.0 months; n=15; daily subcutaneous injection of 20 µg teriparatide), and bisphosphonate treatment (average, 13.0 months; n=15; weekly oral administration of 17.5 mg risedronate).
Summary · context
All patients underwent PLF with a local bone graft. Fusion rate and duration of bone union were evaluated 1.5 years after surgery.
Report a problemFND-2624071705
06HumanObservational studyEfficacy outcome
In women after lumbar fusion, long-duration teriparatide had a shorter time to bone union than short-duration treatment.
In plain wordsIn women after lumbar fusion, longer teriparatide treatment was linked to faster bone union than shorter treatment.
Peptide
Teriparatide (PTH 1-34)
Outcome
DecreaseTime to bone union with long versus short treatment
Study
n = 30
Comparator
short-duration teriparatide
Outcome group
Bone and joint · Musculoskeletal
Studied dose
20 µg daily · subcutaneous · 13.0 monthsAs given in this study (human).
Measurements
Time to bone union
7.5 months
long-duration teriparatide
Time to bone union
8.5 months
short-duration teriparatide
Source sentences
Summary
Bone union rate and average duration for bone union were 92% and 7.5 months in the long-duration treatment group, 80% and 8.5 months in the short-duration treatment group, and 70% and 10.0 months in the bisphosphonate treatment group, respectively.
4 context sentences(design, population, supporting numbers)
Summary · context
Results of bone union rate and average duration for bone union in the teriparatide treatment groups were significantly superior to those in the bisphosphonate treatment group (p<0.05); whereas, significantly superior results were observed in long-duration treatment group when compared with short-dur…
Summary · context
short-duration treatment (average, 5.5 months; n=15; daily subcutaneous injection of 20 µg teriparatide)
Summary · context
long-duration treatment (average, 13.0 months; n=15; daily subcutaneous injection of 20 µg teriparatide), and bisphosphonate treatment (average, 13.0 months; n=15; weekly oral administration of 17.5 mg risedronate).
Summary · context
All patients underwent PLF with a local bone graft. Fusion rate and duration of bone union were evaluated 1.5 years after surgery.
Report a problemFND-2624071706

AI wrote and checked these results. AI can make mistakes, so check important results against the source.

Version history

PepBank keeps every version of the data on this study. Status changes from Retraction Watch, Europe PMC and Crossref are listed with their source.

Version 2Current
22 Oct 2026, 02:26 UTC
Study results updated
Version 1
21 Oct 2026, 18:59 UTC
First added · source update from Europe PMC

Subjects

Terms as the source lists them.

Publication types

Keywords

PepBank is a research reference. Talk to a doctor before you use any peptide.